Twenty-five process QIs referred to molecular profiling (e.g., ER/PR and HER-2 status) in breast cancer prior to treatment delivery and was found in seven of the 11 studies that included breast cancer in their tumour groups of focus [26], [30], [33], [36], [37], [38], [40]. The gene discussed is ERBB2; the disease is neoplasm.